Gilead Sciences Announces Large Buyback
“Lastly Gilead Sciences is buying back $1 billion worth of its stock over the next year. This comes after better than expected results earlier this week…” — CNBC’s Squawk on the Street 1/29/2010
Pfizer Earnings Preview: Fourth Quarter 2009
Pfizer (PFE: 18.91 +0.69%) is scheduled to report their fourth quarter 2009 results before the market opens on Wednesday, February 3rd. Based on analysis from EarningsPreviews.com, Pfizer is expected to report better than expected quarterly results tha…
Keryx / Aeterna Drug Shows Promise In Late-Stage Colon Cancer Patients
The ProActive News Room website for Keryx Biopharma (NASDAQ: KERX) has been updated to include the Company’s most recent corporate presentation and the GI-ASCO 2010 poster presentation from last weekend. In the randomized Phase 2 trial, perifosine + ca…
J&J Beats, Guidance Disappoints
Johnson & Johnson (JNJ) reported fourth quarter earnings of 79 cents, which was impacted by a restructuring charge. However, excluding extraordinary items, the company’s earnings per share came in at $1.02, surpassing the Zacks Consensus Estimate…
Amlylin Pharma (NASDAQ: AMLN): Upgraded To Buy At Citigroup
Amylin Pharma (NASDAQ:AMLN) is getting lots of very positive commentary this morning after the FDA issued a press release announcing the approval of Novo Nordisk’s Victoza (liraglutide), a once-daily GLP-1 for diabetes.
Indices End The Week Getting Crushed Again!
The stock market indices got crushed Friday to end the week on a down note, and it wasn’t pretty.
The indices rolled over hard mid-day and closed at the lows for the day going away, with Dow down nearly 217 at 10172.98. The S&P 500 lost nearly 2…
Genzyme’s Outlook Stabilizing
Genzyme Corp. (GENZ) reports fourth-quarter results on February 17, with the current Zacks Consensus Estimate at 20 cents per share. Recent revisions to the quarterly estimate have been in both directions, with a very modest upward (positive) bias. Of …
Earnings Preview: St. Jude Medical, Inc. (NYSE:STJ) – Sustaining Profitability
St. Jude Medical, Inc, one of the world leaders in the development of state-of-the-art technology for cardiac rhythm management devices, is scheduled to report December 2009 quarter results on Wednesday, January 27, 2010.
UnitedHealth Beats Estimates
UnitedHealth Group’s (UNH) fourth quarter earnings of 81 cents per share were well ahead of the Zacks Consensus Estimate of 73 cents. Results were also ahead of the prior-year period’s earnings of 60 cents. The better-than-expected results reflecte…
RINO International (RINO) Lands 10 Year, $118M Contract
RINO International (RINO) is one of a host of companies I’ve had on my watch list for a few months but have yet to discuss on the website. Today’s 10 year, $118M contract provides a good incentive to introduce the name, at least in a cursory fash…